Human neutrophil peptides 1, 2 and 3 (HNP 1–3): elevated serum levels in colorectal cancer and novel marker of lymphatic and hepatic metastasis

Kemik, Özgür; As, Kemik; Sümer, Aziz; Beğenik, Hüseyin; Pürisa, Sevim; Tüzün, Sefa

doi:10.1177/0960327111412802

Cited by 22 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With this approach, we report in the present study, overexpression of ␣-defensins (HNP 1-3) in H-CC. HNP 1-3 are a group of peptides already identified in various other types of malignancies, including digestive, lung, and kidney cancers [29,[32][33][34][35]. HNP 1-3 are antimicrobial peptides mainly expressed in human neutrophils of the innate immune system but not in normal epithelial cells [36].…”

Section: Discussionmentioning

confidence: 99%

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry

et al. 2014

View full text Add to dashboard Cite

Cholangiocarcinoma (CC) is the second most common primary malignancy of the liver. Although all CC derive from biliary epithelial cells, two main subtypes, hilar (H), and peripheral (P) CC are described. The objective of the study was to compare, using MALDI imaging mass spectrometry (MALDI IMS), in situ proteomic profiles of H- and P-CC in order to assess whether these subtypes may express different markers and to describe their respective localizations. Twenty-seven CC (16 P-CC and 11 H-CC) were subjected to MALDI IMS. Proteomic data were submitted to a dedicated cross-classification comparative design, enabling comparison of the entire generated spectra. Immunohistochemistry was performed for validation. Comparative analysis yielded a list of 19 differential protein peaks for the two subtypes, 14 of which were overexpressed in H-CC and five in P-CC. Among H-CC protein markers, most discriminant were human neutrophil peptides 1-3 that were expressed mainly by tumor cells and S100 proteins (A6 and A11) that were restricted to the stromal area. In P-CC, thymosin β4 was diffusely overexpressed. These results highlight the potential of MALDI IMS to discover new relevant biomarkers of CC and to characterize the heterogeneity of the two different subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Proteomic approach was used to identify differentially expressed proteins between CRC and normal colon mucosa in our study and we successfully identified 802 proteins, including 68 of them were defined as differentially expressed proteins. Some of these differentially expressed proteins played important roles in CRC genesis, developing and progressing, such as GRP78, neutrophil defensin 3, plectin, and tropomyosin beta chain (14)(15)(16)(17). In order to reveal biological functions of these differentially expressed proteins, we used some integral bioinformation tools.…”

Section: Discussionmentioning

confidence: 99%

Identification of Differentially Expressed Proteins of Normal and Cancerous Human Colorectal Tissues by Liquid Chromatograph-Mass Spectrometer Based on iTRAQ Approach

Fan

Wang

et al. 2015

Cancer Investigation

View full text Add to dashboard Cite

Liquid chromatograph-mass spectrometer (LC/MS) based labeled with isobaric mass tags for relative and absolute quantitation (iTRAQ) analyses were performed to identify differentially expressed proteins from normal and cancerous human colorectal tissues. Around 802 proteins were identified, 68 proteins of which were defined as differentially expressed proteins. Bioinformatics analysis indicated that these differentially expressed proteins correlated with several specific cellular processes and pathways which have relationships with pathological changes of colorectal cancer (CRC). EHD2 were selected to verify its expression patterns and localization using western blotting and immunohistochemistry respectively. LC/MS-based iTRAQ proteomic approach would provide new information about the character of CRC.

show abstract

“…Earlier studies have found discrepancies in HNP levels in sera [ 39 – 41 ], plasma [ 42 ] or biological fluids [ 41 ] of normal and various diseases including infectious diseases [ 41 , 43 , 44 ], metabolic diseases (e.g., diabetes) [ 45 , 46 ], cardiovascular disease [ 2 , 47 ], cancers of urinary bladder [ 42 ], colorectal cancer [ 40 ], colorectal adenoma [ 48 ] and colon carcinoma [ 39 ]. It has been reported that normal plasma levels of HNPs range from undetectable to 50–100 ng/ml.…”

Section: Discussionmentioning

confidence: 99%

Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients

et al. 2016

View full text Add to dashboard Cite

BackgroundAtherosclerosis is a multifactorial disorder of the heart vessels that develops over decades, coupling inflammatory mechanisms and elevated total cholesterol levels under the influence of genetic and environmental factors. Without effective intervention, atherosclerosis consequently causes coronary heart disease (CHD), which leads to increased risk of sudden death.Polymorphonuclear neutrophils play a pivotal role in inflammation and atherogenesis. Human neutrophil peptides (HNPs) or alpha (α)-defensins are cysteine-rich cation polypeptides that are produced and released from activated polymorphonuclear neutrophil granules during septic inflammation and acute coronary vascular disorders. HNPs cause endothelial cell dysfunction during early atherogenesis. In this cross-sectional study, control, hyperlipidemia and CHD groups were representative as atherosclerosis development and CHD complications. We aimed to assess the correlation between α-defensin expression and the development of CHD, and whether it was a useful predictive indicator for CHD risk.MethodsFirst, DNA microarray analysis was performed on peripheral blood mononuclear cells (PBMCs) from Thai control, hyperlipidemia and CHD male patients (n = 7). Gene expression profiling revealed eight up-regulated genes common between hyperlipidemia and CHD patients, but not controls. We sought to verify and compare α-defensin expression among the groups using: 1) real-time quantitative RT-PCR (qRT-PCR) to determine α-defensin mRNA expression (n = 10), and 2) enzyme-linked immunosorbent assay to determine plasma HNP 1–3 levels (n = 17). Statistically significant differences and correlations between groups were determined by the Mann–Whitney U test or the Kruskal–Wallis test, and the Rho-Spearman correlation, respectively.ResultsWe found that α-defensin mRNA expression increased (mean 2-fold change) in the hyperlipidemia (p = 0.043) and CHD patients (p = 0.05) compared with the controls. CHD development moderately correlated with α-defensin mRNA expression (r = 0.429, p = 0.023) and with plasma HNP 1–3 levels (r = 0.486, p = 0.000).ConclusionsIncreased α-defensin expression is a potential inflammatory marker that may predict the risk of CHD development in Thai hyperlipidemia patients.

show abstract

Human neutrophil peptides 1, 2 and 3 (HNP 1–3): elevated serum levels in colorectal cancer and novel marker of lymphatic and hepatic metastasis

Abstract: Preoperative high plasma HNP 1-3 levels are associated with colorectal cancer. The HNP 1-3 levels may procure information on patients with lymph node or hepatic metastasis.

Cited by 22 publications

References 23 publications

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry

Identification of Differentially Expressed Proteins of Normal and Cancerous Human Colorectal Tissues by Liquid Chromatograph-Mass Spectrometer Based on iTRAQ Approach

Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients

Contact Info

Product

Resources

About